Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term sc [Secondary]. Found 5 abstracts

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine. 2007 May 31;356(22):2271-81.
Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer N. Rectal cancer clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2005 Jul;3(4):492-508.
Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer N. Colon cancer clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2005 Jul;3(4):468-91.
Langer CJ. Role of zoledronic acid in the setting of bone metastases from non-small-cell lung cancer. Clinical lung cancer. 2005 Jan;6(5):314-6, 2005 Mar.
Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clinical Colorectal Cancer. 2005 Jul;5(2):108-13.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term sc [Secondary]

sc [Secondary] Antineoplastic Combined Chemotherapy Protocols pa [Pathology] dt [Drug Therapy] tu [Therapeutic Use] Female 0 (Antineoplastic Combined Chemotherapy Protocols) Lung Neoplasms Middle Aged th [Therapy] aa [Analogs & Derivatives] 0 (Antineoplastic Agents) di [Diagnosis] mo [Mortality] Bone Neoplasms Antineoplastic Agents st [Standards] Medical Oncology su [Surgery] Use] Neoplasm Staging Brain Neoplasms Lymphatic Metastasis Male ae [Adverse Effects] Liver Neoplasms tu [Therapeutic Adjuvant Chemotherapy et [Etiology] Hematologic Diseases Secondary Hypertrophic Osteoarthropathy 0 (Folfox protocol) Colostomy 0 (Diphosphonates) 51-21-8 (Fluorouracil) Squamous Cell Carcinoma Imidazoles EC 2-7-1-37 (Protein Kinases) Philadelphia Interferon-alpha Adult Diphosphonates Survival Analysis Neoplasm Metastasis Sirolimus Rectal Neoplasms Colonic Neoplasms Adenocarcinoma Organoplatinum Compounds Colectomy EC 2-7-1 (mTOR protein) co [Complications] Renal Cell Carcinoma ci [Chemically Induced] Retrospective Studies Kidney Neoplasms Protein Kinases Colorectal Neoplasms Prognosis Fluorouracil 7689-03-4 (Camptothecin) 0 (Interferon-alpha) Colonic Polyps Camptothecin Protein Kinase Inhibitors Disease Progression Neoplasm Invasiveness Multivariate Analysis 80 and over Aged Leucovorin Aged 0 (Protein Kinase Inhibitors) ep [Epidemiology] NIH Research Support-Extramural Survival Rate 0 (IFL protocol) Lymph Node Excision Adjuvant Radiotherapy Risk Assessment 0 (Imidazoles) Salvage Therapy tu [Therapeutic Use] Proportional Hazards Models 118072-93-8 (zoledronic acid) Incidence 0 (cci 779) 53123-88-9 (Sirolimus) rt [Radiotherapy] 0 (Organoplatinum Compounds) 58-05-9 (Leucovorin)
Last updated on Wednesday, February 05, 2020